Company ProfilePremium

Blueberry NFT CO., LTD.

Company Profile Analysis

Ticker: 044480.KQ주식회사 빌리언스

ESOMAR 23 Corporate BadgeISO Certifications Badge
Blueberry NFT CO., LTD. - Company showcase

Year Founded & Workforce

1973

83 Employees

Blueberry NFT CO., LTD. logo

Blueberry NFT CO., LTD. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Blueberry NFT CO., LTD. Overview

Billions Co., Ltd. is a small-cap KOSDAQ hybrid. A 53-year-old latex-rubber hygiene manufacturer, historically Korea's leading domestic condom maker under the Unidus name, sits alongside an entertainment business built through acquisitions from 2023. That business manages actors and singers, produces music and concerts, and, through its subsidiary Billions Plus, produces drama. Since 2017 the listed shell has passed through biotech, pharma-holding, NFT and entertainment identities. Each pivot came with a change of control or a new theme. Since May 2024 the company has sat inside the Humasis–Mirae I&G group, which Stella PE took over in March 2026. Revenue is about KRW 25 billion a year and has carried operating losses for at least five consecutive years. Accumulated deficits approach KRW 100 billion. The company has relied on repeated rights offerings, convertible bonds, a par-value reduction and two share consolidations to stay solvent and listed. Its newest stated direction is advanced manufacturing and aerospace supply-chain investment.


What the company does today. Third-party summaries of the company's filings describe two operating pillars:

  1. Healthcare/hygiene rubber products. Manufacture, wholesale, retail and export of condoms, rubber finger cots (고무골무) and medical gloves. The registered industry classification remains "rubber apparel and other sanitary unvulcanized rubber products manufacturing." The condom brand currently catalogued is Long Love (롱러브). In the 2020–2022 period the company also sold KF-94 masks and distributed vitamins, placenta products and health foods. Investing.com's profile still lists these lines, but they appear to date from the Kyungnam Biopharma era.

  2. Entertainment. Artist management of actors and singers, album planning and music production, concert promotion, and film/drama production. Production runs through the subsidiary Billions Plus, which produced the 2025 Coupang Play series Newtopia. StockHub's summary of the filings lists the content activities as planning, developing and supplying content, producing and managing drama and film in several genres, artist management, concert planning, and music/album distribution and marketing.

The company's own description. The latest annual-report wording could not be retrieved verbatim. In November 2025, when merging the subsidiary XYG Studio, management framed the goal as evolving from a manufacturing-based listed company into an integrated IP, music and video production company. The merger brought planning, casting, music and production under one corporate roof (Money Today, 28 Nov 2025).

Business and revenue model.

Hygiene products: manufactured-product sales, B2C and B2B, with a domestic retail and export history.

Entertainment: management-fee and commission revenue from artist activity (advertising, drama/film appearances), album and merchandise sales, concert and tour revenue, and production revenue from content sold or licensed to OTT platforms.

Product vs. service mix: not disclosed. Separate-basis cost of sales was about 80% of revenue in FY2025 (179.5 of 225.6). That is consistent with a revenue base dominated by low-margin pass-through items such as artist settlements, merchandise and goods, rather than high-margin licensing.

  • No subscription or licensing revenue streams of significance have been disclosed.

Value-chain position.

  • In hygiene products, Billions is an upstream/midstream manufacturer. It converts latex into finished goods at its Jeungpyeong site.

  • In entertainment, it is a mid-tier talent agency, with a nascent in-house production arm and concert/album capability. It has no platform or distribution ownership.

Customer types and end-markets. Domestic Korean consumers and retailers, plus public-sector buyers, for hygiene products. Historical exports went to the WHO and UNFPA (1998). Korean broadcasters, OTT platforms (Coupang Play, Netflix, Disney+, Tving), advertisers and concert audiences in Korea and Asia for entertainment. Management has signalled an intended Japan music partnership (Nov 2025).

Independent characterization. Billions is best understood as a restructuring vehicle inside a listed-company group, not as a focused operating company. Its strategic narrative has changed four times in nine years (biotech → pharma holding → NFT → entertainment → aerospace investing). Its largest balance-sheet items are financial: equity-method stakes, convertible bonds and cash from recent placements. They are not operating assets. The entertainment roster is real and recognisable, and the hygiene business provides a modest revenue floor. But the company has not demonstrated that either business can cover interest and overhead.

Strategy

  1. Integrated entertainment company. The company states it wants to become an end-to-end IP company spanning planning, casting, music, video production and performance. The vehicle is the absorption of XYG Studio (Nov 2025) plus the production subsidiary Billions Plus. The aim is to run planning–casting–production as one process targeting global OTT platforms (Money Today, Nov 2025).

  2. Premium vocalist music and concert platform. The company is building around established K-pop vocalists (Kim Sung-kyu, Nam Woo-hyun, Jung Eun-ji, Kim Yong-jun, Yoon Ji-sung). It plans directly promoted solo concerts, overseas tours, OSTs and project albums, and a Japanese record-label partnership.

  3. Aggressive roster expansion. Management has stated an intention to grow management scale through aggressive artist recruitment. 2026 signings include Kim Ha-neul (2025), Yoo Ah-in, Lee Jung-jin and Go Won-hee.

  4. Advanced manufacturing / aerospace. The Tris stake (May 2026) was framed as a strategic step toward advanced manufacturing and global aerospace investment and M&A, not merely a financial investment (Asia Economy; Money Today, 27 May 2026). The parent Humasis separately added semiconductor materials and equipment to its business purposes in March 2026.

  5. Capital-structure repair and listing maintenance. Measures include the par reduction (2025), equity raises (2025, 2026) and two 5:1 consolidations (2026). The consolidations were explicitly linked to the Korea Exchange's planned delisting rule for stocks persistently priced below KRW 1,000, effective from July 2026 (The Bell, Apr 2026; Dailypharm, Mar 2026).

Initiatives announced in the last 24 months.

Sustainability/ESG commitments, cost programs, medium-term financial targets or guidance: none publicly disclosed.

Products & Services

Healthcare / Hygiene Rubber Products

Product / brandDescriptionTarget customerLaunch / statusPricingSource
Long Love (롱러브) condomsLatex condom brand currently catalogued for the companyConsumers via retail/onlineActive (year not disclosed)—THE VC
Historical condom brands ("Million," "Ecstasy," Unidus range)Domestic condom brands of the 1990s–2000sConsumers; WHO/UNFPA exportLegacy—Wikipedia
Rubber finger cots (고무골무)Protective latex finger coversIndustrial and medical buyersActive—Digital Today (company description)
Medical / surgical glovesLatex gloves; KS-marked since 1988Hospitals, public procurementActive—Digital Today; Wikipedia
KF-94 masksHealth masks (COVID-era)Consumers, public sector2020–2022; current status not disclosed—Investing.com; THE VC tech keywords
Vitamins, placenta products, health foodsDistribution of Kyungnam Pharm-related goodsConsumersHistorical; status not disclosed—Investing.com profile

Entertainment — Artist Management (selected roster, per company website and press)

Artist groupNamed artistsJoinedSource
Actors (legacy Star Village)Park Myung-shin, Jung Suk-yong, Jo Hee-bongMar 2023Wikipedia
Actors (legacy J-Flex)Lee Jun-young, Ko Chang-seok, Han Sang-jin, Kwon So-hyun, Kim Kang-min, Choi Ji-hyeJul 2023Wikipedia
Actors (legacy XYG Studio)Jo Bo-ah, Jung Sung-il, Jang Yoon-ju, Geum Hae-na, Kim Jae-cheol, Ji Hye-wonMerged Nov 2025Money Today; Wikipedia
Actors signed 2023–2026Song Ji-woo, Lee Kyu-han, Wang Ji-won, Lee Il-jun, Lee Yoo-jun, Oh Se-young, Heo Sung-tae, Son Hyun-joo, Kim Ha-neul, Yu Ha-jin, Lee Ha-eun, Park Wan-hyeong, Choi Moo-sung, Yoo Ah-in (Aug 2026), Lee Jung-jin (Sep 2026), Go Won-hee (Sep 2026)VariousWikipedia; IS Plus; TV Report
Singers / vocalistsKim Sung-kyu (INFINITE), Nam Woo-hyun (INFINITE), Jung Eun-ji (Apink), Kim Yong-jun (SG Wannabe), Yoon Ji-sung (ex-Wanna One)2024–2025Money Today; Wikipedia

Entertainment — Music, Concerts & Merchandise

OfferingDescriptionDateSource
Lee Jun-young, Last DanceMini-album2,025Wikipedia
Jung Eun-ji, Summer, I5th mini-album (first in ~6 years) and solo concert11 Aug 2026THE VC news feed
Nam Woo-hyun, 2X82nd full-length album, 16 tracks, title track "DEVIL"14 Oct 2026THE VC news feed (TenAsia; MHN Sports)
Nam Woo-hyun, 식목일VI – EVER GREENSeoul solo concert and Asia tour (10th solo anniversary)Q4 2026MHN Sports via THE VC
Lee Jun-young 2027–2028 season's greetingsTwo-year merchandise productAnnounced Oct 2026TenAsia via THE VC
Japan music projectPlanned partnership with a major Japanese record companyStated as intended within 2025; completion not confirmedMoney Today (28 Nov 2025)

Entertainment — Content Production (Billions Plus)

TitleFormatPlatformYearNotesSource
NewtopiaDrama series (Park Jung-min lead)Coupang Play2,025Ranked highly on Coupang's global OTT index per companyMoney Today; Wikipedia

Discontinued / Dormant Lines (Biogenetics and Blueberry NFT eras)

LineDescriptionPeriodCurrent statusSource
ASLAN-001 (varlitinib), ASLAN-003Korean rights to oncology candidates2,019No disclosed development activity since 2021Edaily
Baseball player NFT cardsKPBPA publicity rights2021–2022—Blockmedia
ELVN K League NFT platformGoal and highlight NFTsLaunched Sep 2022—Dealsite
V-League volleyball NFTsSold on OpenSea; Korbit marketplace MOU2,022—The Value News
STAN by BArt-NFT marketplace and gallery2,021—Asia Economy
PixelgroundP2E game with Meta Kongz and Doge Sound Club NFTs2,022—Dealsite
NFT PASSTicket NFTs for Ultra Korea 2022 and the Jarasum Jazz Festival2,022—TokenPost

Financial Narrative

Income Statement — Consolidated (KRW 100M)

Source: OpenDART via Bullstory (consolidated). Margins computed. FY2025 net loss reported as KRW 74 (100M) by The Bell (Apr 2026), which differs by rounding.

Revenue CAGR FY2021–FY2025: −0.5% a year (258 → 253). Revenue has swung with consolidation-perimeter changes rather than organic growth.

Income Statement — Separate (Parent-Only) and TTM (KRW 100M)

The columns below are trailing-twelve-month (TTM) windows ending on the stated quarter. "TTM Dec-2025" equals the full FY2025.

Source: DataHero/ValueLine, separate (parent-only) TTM figures, updated through 2Q 2026. Margins computed. Derivative losses at TTM Jun-2025 and Sep-2025 shown as 0 where the source reported N/A.

Derived EBITDA (operating income + depreciation in cost of sales and SG&A; separate basis):

  • FY2025: −2.8 + 2.7 + 9.8 = KRW 9.7 (100M)

  • TTM Jun-2026: 0.4 + 3.1 + 9.5 = KRW 13.0 (100M)

These are analyst-derived figures, not company-reported.

Balance Sheet — Separate (Parent-Only), KRW 100M

The table covers FY2022–FY2025. The 1H 2026 values, as of 30 Jun 2026, are given in the commentary below because the table is limited to fiscal years.

Source: DataHero/ValueLine, separate basis. Total debt, net debt and working capital are computed by the analyst.

1H 2026 (30 Jun 2026, separate).

  • Total assets KRW 686.4 (100M); current assets 436.0.

  • Cash 242.8 plus short-term financial assets 57.8.

  • Short-term borrowings 24.9; short-term bonds 100.9; total debt ~125.8; net cash ~KRW 174.8 (100M) including short-term financial assets.

  • Total liabilities 230.6; equity 455.8.

  • Retained deficit −945.5; capital surplus 1,228.1.

Consolidated balance-sheet footnote data. Total assets: 1,723.4 (FY2022), 1,996.1 (FY2023), 488.4 (FY2024). Total liabilities: 657.1 / 1,071.5 / 268.2. Equity: 282.3 / 160.0 / 220.6 (DataHero/ValueLine, "equity-method applied" footnote series; the FY2024 figures match media reports of the consolidated FY2024 balance sheet). The Bell reports a consolidated accumulated deficit of KRW 974 (100M) at end-FY2025.

Cash Flow

Source: OpenDART via Bullstory (OCF). PP&E is small (separate KRW 40.6 (100M) at FY2025), which implies capex is minor.

Equity financing — the company's real "cash flow".

Ratios

Computed from DataHero/ValueLine separate balance-sheet data. THE VC independently reports a FY2025 current ratio of 91.9%, which agrees.

Single-year and TTM ratios (separate basis).

ROE FY2025: −69.4 / avg equity 236.5 = −29.3%. ValueLine reports trailing ROE of −41.5% (Oct 2026).

ROA FY2025: −69.4 / avg assets 477.7 = −14.5%.

Interest coverage FY2025: operating income −2.8 / interest 25.6 = negative (−0.1x). On derived EBITDA: 9.7 / 25.6 = 0.38x.

Net debt / EBITDA FY2025: 7.2 / 9.7 ≈ 0.7x. Net cash at 1H 2026.

Asset turnover FY2025: 225.6 / 477.7 = 0.47x.

Current ratio 1H 2026: 1.92x. D/E 1H 2026: 0.28x.

ROIC, cash conversion cycle: not computable from retrieved data; marked not disclosed.

Commentary — Trends, Inflections, Drivers

Revenue. Consolidated revenue has moved in a band of KRW 25–71 billion. The spikes come from acquisitions and changes in consolidation scope, not organic momentum: Kyungnam Pharm in FY2022, then entertainment subsidiaries in FY2024. On a separate basis, revenue fell from a TTM peak of 291.8 (Jun-2025) to 225.6 in FY2025, then recovered to 245.8 TTM to Jun-2026. That pattern is consistent with lumpy entertainment project revenue, such as album and concert cycles and drama delivery.

Operating profitability. Losses have narrowed: consolidated operating loss went from −56 (FY2021) to −8 (FY2025), and separate operating income was break-even on a TTM basis in 2026. This is the most constructive data point in the file. Gross margin on the separate basis is thin, at roughly 18–22%, which leaves little room to absorb SG&A of KRW 47–56 (100M).

Below-the-line losses dominate. In every year except FY2024, net loss vastly exceeds operating loss. The recurring drivers are:

  • Interest expense of ~KRW 25 (100M) a year, mostly on convertible bonds.

  • Equity-method losses of KRW 16–26 (100M) from associates, principally Kyungnam Pharm.

  • Impairments and other non-operating charges.

  • In 1H 2026, a KRW 149.9 (100M) derivative loss, consistent with fair-value remeasurement of CB conversion options after the share price fell and the conversion terms reset.

FY2024's positive net income of KRW 86 (100M) was a non-operating event. It should not be treated as recurring.

Balance sheet. The FY2023 low point (equity 132.8; D/E 1.7x) prompted:

  • the 2025 par-value reduction, which eliminated deficits against share capital and created a KRW 162.6 (100M) capital-reduction surplus;

  • two equity raises totalling ~KRW 21.6bn.

By June 2026 the parent held net cash and an equity base of KRW 455.8 (100M). However, this was funded largely by its own parent, Humasis, and accompanied by a cumulative 25:1 share consolidation.

Cash flow. Operating cash flow turned modestly positive (KRW 7 (100M)) in FY2024–FY2025 after three negative years. That is not sufficient to cover interest.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityRelationshipActivityStatus / notesSource

Billions Plus (빌리언스플러스)

Subsidiary

Film/drama production; produced Newtopia (Coupang Play, 2025)

Founded Mar 2012; CEO Kim Woo-jae; 4 employees (Jun 2026)

THE VC; Money Today

XYG Studio

Former subsidiary

Actor management

Absorbed into parent, Nov 2025

Money Today; Wikipedia

Blade Music / Blade Creative / Blade Media

Former subsidiaries

Music, creative, media

Absorbed Jun 2024

Wikipedia

Star Village Entertainment

Former acquiree

Actor management

Acquired Jan 2023; merged Mar 2023

Wikipedia

J-Flex

Former acquiree

Actor management

Acquired Jul 2023; merged Sep 2023

Wikipedia

Blueberry Meta

Former subsidiary (NFT)

Sports NFT platforms (ELVN)

Current status not disclosed

Dealsite (2022)

Kyungnam Pharm (경남제약)

Associate (largest shareholder at 19.84% as of Oct 2024)

OTC pharma and health supplements (Lemona)

Cross-holding: Kyungnam Pharm holds Billions convertible bonds

Daum/Asia Toyo (Oct 2024); Digital Today

Tris (트리스)

Minority investment (3.97%)

Stainless/special-alloy pipe and tubes

Acquired May 2026

Asia Economy

Segment (As Described) Overview

Segment (as described)ContentsProducts / services

Healthcare / hygiene goods

Latex-rubber manufacturing at Jeungpyeong

Condoms (Long Love), rubber finger cots, medical gloves; historically masks

Entertainment / content

Artist management, music and concerts, drama/film production

Actor and singer management, albums and season's-greetings merchandise, concerts and tours, OTT drama production (Billions Plus)

Revenue by Segment (KRW) and Segment Margins & Growth (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue consolidated (KRW 100M)

258706290417253

Revenue YoY growth consolidated (%)

0173.6-58.943.8-39.3

Income Statement (KRW) and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue consolidated (KRW 100M)

258706290417253

Operating income consolidated (KRW 100M)

-56-31-6-11-8

Net income consolidated (KRW 100M)

-318-247-30886-73

Operating cash flow consolidated (KRW 100M)

-20-16-3477

Operating margin consolidated (%)

-21.7-4.4-2.1-2.6-3.2

Net margin consolidated (%)

-123.3-35.0-106.220.6-28.9

Income Statement (KRW) and Margin Analysis (%) (TTM Jun-2025–TTM Jun-2026)

MetricTTM Jun-2025TTM Sep-2025TTM Dec-2025TTM Mar-2026TTM Jun-2026

Revenue separate (KRW 100M)

291.8277.8225.6256.5245.8

Cost of sales separate (KRW 100M)

238.5228.6179.5204.4192.0

Gross profit separate (KRW 100M)

53.249.146.052.053.8

SG&A separate (KRW 100M)

56.448.648.847.453.3

Operating income separate (KRW 100M)

-3.10.4-2.84.60.4

Interest expense separate (KRW 100M)

24.325.125.625.524.3

Derivative losses separate (KRW 100M)

004.84.8149.9

Equity-method P&L separate (KRW 100M)

-16.8-15.6-18.8-17.1-25.6

Pre-tax income separate (KRW 100M)

-29.3-13.9-70.3-54.5-199.3

Net income separate (KRW 100M)

-28.0-12.9-69.4-53.8-189.0

Gross margin separate (%)

18.217.720.420.321.9

Operating margin separate (%)

-1.10.1-1.21.80.2

EPS separate adjusted for 25:1 consolidation (KRW)

-1,571.2-644.4-2,706.4-1,800.3-4,187.1

Balance Sheet (KRW)

MetricFY2022FY2023FY2024FY2025

Total assets separate (KRW 100M)

471.9457.7475.6479.7

Current assets separate (KRW 100M)

130.7180.3132.1206.3

Cash and equivalents separate (KRW 100M)

44.680.458.2131.8

Short-term borrowings separate (KRW 100M)

0010.024.9

Short-term bonds incl. CBs separate (KRW 100M)

87.3182.297.0113.9

Current portion of LT debt separate (KRW 100M)

43.142.442.30.2

Long-term borrowings separate (KRW 100M)

0.20.60.20

Total debt separate (KRW 100M)

130.6225.2149.5139.0

Net debt separate (KRW 100M)

86.0144.891.37.2

Current liabilities separate (KRW 100M)

217.6318.7245.4225.4

Total liabilities separate (KRW 100M)

218.9324.9253.6228.6

Total equity separate (KRW 100M)

253.0132.8222.0251.0

Goodwill separate (KRW 100M)

011.911.911.9

Goodwill and intangibles separate (KRW 100M)

2.314.715.816.2

Investments in associates separate (KRW 100M)

10.740.1160.2118.6

Investments in subsidiaries separate (KRW 100M)

211.3157.200

Working capital separate (KRW 100M)

-86.9-138.4-113.3-19.1

Retained earnings deficit separate (KRW 100M)

-729.6-906.2-905.2-969.2

Cash Flow (KRW)

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow consolidated (KRW 100M)

-20-16-3477

Dividends paid (KRW 100M)

00000

Share buybacks (KRW 100M)

00000

Instrument by Date

DateInstrumentAmount (KRW 100M)CounterpartySource

2025 (Jun–Sep)

Rights offering (40.0M new shares)

~116

Shareholders; Humasis subscribed

Dealsite; Digital Today

Mar–Apr 2026

Third-party allotment (39,215,688 shares)

~100

Originally Supi Value-up / Supi Synergy funds; changed to Humasis on 9 Apr 2026

Dealsite; Money Today

2022–2026

Multiple convertible bonds (four CBs on the corporate registry); repeated refixings

—

Including Kyungnam Pharm and Humasis

THE VC; Dealsite; Digital Today

“—” = not publicly disclosed.

Financial Ratios (x) and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025

Current ratio separate (x)

0.600.570.540.92

Debt to equity separate (x)

0.521.700.670.55

Liabilities to equity separate (x)

0.872.451.140.91

Equity to assets separate (%)

53.629.046.752.3

Region Overview

RegionActivityEvidence

Korea (domestic)

Overwhelming majority of revenue: domestic hygiene-product sales, artist management, Korean OTT and broadcast work, domestic concerts

Business descriptions; no export split disclosed

Japan

Planned record-label partnership (stated Nov 2025); K-vocalist fan base

Money Today (Nov 2025)

Asia (multi-country)

Nam Woo-hyun Asia tour announced Oct 2026

MHN Sports via THE VC

Global (historical)

Condom exports to WHO/UNFPA (1998); Kenya export contract

Wikipedia (Munhwa Ilbo)

Global (OTT reach)

Newtopia: distributed via Coupang Play's global index (per company)

Money Today

Valuation Multiples (KRW)

MetricFY2022FY2023FY2024FY2025

Year-end share price adjusted (KRW)

35,61226,91811,2917,400

Year-end market cap (KRW 100M)

483.5385.2192.7238.7

Shares outstanding adjusted (10000 shares)

142149178323

Share Price & Returns

PeriodStart (adjusted, KRW)End (KRW, 15 Oct 2026)ReturnBasis

YTD 2026

7,400 (31 Dec 2025)

2,900−60.8%

ValueLine

~1 year

~9,525 (2 Oct 2025 close of KRW 381 × 25)

2,900

~−69.6%

Digital Today; analyst adjustment

~3 years (from end-2023)

26,9182,900−89.2%

ValueLine

~4 years (from end-2022)

35,6122,900−91.9%

ValueLine

Valuation Multiples

MultipleBillionsBasis / comment

P/E

n/m (loss-making); ValueLine shows −1.07x trailing

ValueLine

P/B

0.44x

Separate equity KRW 455.8 (100M), Jun 2026

EV / Sales

~0.03x

EV ≈ market cap 202 + debt 125.8 − cash 242.8 − ST financial assets 57.8 ≈ 27.2; ÷ separate TTM revenue 245.8 × 0.25 adj. Unadjusted: 27.2 / 245.8 = 0.11x. Analyst-derived; excludes CB derivative liabilities and associate stakes.

EV / EBITDA

~2.1x

27.2 / derived TTM EBITDA 13.0. Analyst-derived; low-quality EBITDA.

Analyst Conclusions

Management guidance: none published. Consensus growth expectations: none.

Bull Case

  1. Operations are close to break-even and the balance sheet is now net cash. Separate TTM operating income turned positive in 2026. At 1H 2026 the parent held ~KRW 30bn in cash and short-term financial assets against ~KRW 12.6bn of debt. With market cap at ~0.44x book, a sustained operating profit could drive a re-rating.

  2. Roster depth with near-term monetisation catalysts. Q4 2026 brings the Nam Woo-hyun LP and Asia tour, Jung Eun-ji's solo activity, Lee Jun-young's post-Four Hands demand, and new veteran signings. Billions Plus offers production upside on OTT.

  3. A financially stronger owner. Stella PE's group package includes Humasis, which reportedly holds more than KRW 200bn in cash. That reduces funding risk and opens potential for asset injections or strategic deals. The Tris stake ties Billions to an aerospace narrative with a contract running to 2039.

Bear Case

  1. The equity story is serially dilutive. Shares outstanding went from 40.7M (mid-2025) to more than 119M pre-consolidation equivalent within a year. Two 5:1 consolidations then followed. A 1H 2026 derivative loss of ~KRW 15bn shows the CB overhang remains costly.

  2. Below-the-line losses persist structurally. Interest of ~KRW 2.5bn a year and associate losses of ~KRW 2–2.6bn a year exceed operating EBITDA of ~KRW 1.0–1.3bn. Net losses therefore continue even at operating break-even.

  3. Strategic drift and governance risk. Four identities in nine years, a controversial signing and minority-shareholder disputes at the parent suggest capital allocation may be driven by group or theme considerations rather than shareholder returns in the listed entity.

Key Catalysts and Monitorables (next 12 months)

ItemWhat to watch
Q3 2026 quarterly report (expected ~mid-Nov 2026)Whether separate operating income stays positive; size of CB derivative remeasurement
Share price vs. KRW 1,000 thresholdAlready at ~KRW 2,900; another collapse would revive delisting risk
CB conversions / refixingsRemaining CB balance (KRW 100.9 (100M) at Jun-2026) and new issuance
Stella PE group restructuringAsset transfers, mergers or sale of Billions or Kyungnam Pharm stakes
New CEO Kim Ki-heung's strategyFirst public strategy articulation; board composition disclosure
Artist pipelineYoo Ah-in's Vampir reception; Q4 2026 concerts and tours; Japan label deal
Tris investmentFollow-on investments or a broader aerospace/advanced-manufacturing move
FY2026 annual report (Mar 2027)Audit opinion, going-concern language, segment disclosure

Analyst Verdict

Billions Co., Ltd. is not the NFT company named in the request list. It is the latest incarnation of the 1973 Seohung/Unidus latex-rubber business, and since 2023 its identity has been anchored in talent management. The investment case rests less on the condom-and-gloves franchise than on three questions: whether the entertainment roster can become a self-funding operating business, whether the capital structure has finally been reset, and how the new controlling owner, Stella PE, intends to use the group.

The data support a guarded improvement at the operating line. Consolidated operating losses narrowed from KRW 5.6bn (FY2021) to KRW 0.8bn (FY2025), and separate TTM operating income was marginally positive in 2026. The parent's balance sheet now shows net cash and equity of ~KRW 45.6bn. These are not trivial gains.

But the improvement has been bought with shareholder capital: a 2025 par reduction, roughly KRW 21.6bn of parent-funded equity in a year, and two consecutive 5:1 consolidations to avoid low-price delisting. Meanwhile, net income remains deeply negative because of CB interest, derivative remeasurement and associate losses. The 1H 2026 TTM separate net loss of KRW 18.9bn is roughly three-quarters of annual revenue. The accumulated deficit of ~KRW 97bn dwarfs the business's earnings capacity.

The valuation looks optically cheap, at 0.44x P/B and an EV near KRW 2.7bn. That cheapness reflects the market's scepticism about capital allocation in a listed vehicle that has repeatedly reinvented itself around market themes. The disclosure gaps should themselves be treated as a risk factor: no segment or geographic data, an unidentified auditor and board in the sources reviewed, and stale officer data across aggregators.

**Verdict: high-risk, special-situation exposure.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenurePrior roles / backgroundAgeSource

Kim Ki-heung (김기흥)

Representative Director (CEO)

Registered 14 Sep 2026

——

THE VC; Bolta; JobKorea

Park Jong-jin (박종진)

Former Co-CEO, then sole CEO

Until ~Sep 2026

——

JobKorea; Butler; Wikipedia

Shim Hwa-seok (심화석)

Former Co-CEO

From Jul 2023 to ~2026

Held 3.76% of special securities (Aug 2025)

—

Wikipedia; Digital Today

Hong Sang-hyuk (홍상혁)

Former Co-CEO (Blueberry NFT era); CEO of Blueberry Meta

~2021–2023

Liveplex; Mobile One Communication

—

Edaily; The Value News

Oh Sung-won (오성원)

Former Co-CEO (Blueberry NFT era)

~2021–2022

Liveplex; Massive Marketing

—

Edaily

Kim Sung-hoon (김성훈)

Former CEO and largest shareholder (Unidus)

Until 2017

Unidus

Born 1967 (Statbase)

Edaily; Statbase

“—” = not publicly disclosed.

Board & Management Changes

DateChangeContextSource

Jul 2023

Shim Hwa-seok appointed CEO

Coincided with the J-Flex acquisition

Wikipedia

2024–2026

Co-CEO structure (Park Jong-jin and Shim Hwa-seok); earlier Hong Sang-hyuk and Shim Hwa-seok

Post-Humasis acquisition

JobKorea

2026

Changed to Park Jong-jin as sole CEO

Shim Hwa-seok departure

Butler; JobKorea

31 Mar 2026

AGM board reshuffle

Followed the Stella PE takeover of Mirae I&G

THE VC registry; The Bell

14 Sep 2026

Kim Ki-heung registered as CEO

Second wave of post-Stella changes

THE VC registry

Major Shareholders

HolderStakeBasis / dateSource

Humasis Co., Ltd. and 3 related parties

57.12% (3,798,271 shares, post-consolidation)

5% report, 4 Sep 2026

TokenPost

— of which Digital Bridge New Technology Investment Association

5,377,945 pre-consolidation shares (~1.08M post), bought off-market at KRW 1,352 on 11 May 2026

Added as Humasis related party, 18 May 2026

Butler (DART feed)

Kyungnam Pharm (via CB holdings)

18.2% of special securities (Oct 2025); current not disclosed

Cross-holding

Digital Today

Former CEO Shim Hwa-seok

3.76% of special securities (Aug 2025)

Current not disclosed

Digital Today

Institutional investors (top 10)

Not disclosed; no meaningful institutional ownership identified

——

Free float (estimated)

~43% by subtraction (100% − 57.12%), before CB dilution

Analyst estimate

Derived

Competitive Landscape

Key Competitors

CompetitorListingPositioning vs. BillionsSource for identification

Fantagio

KOSDAQ (group affiliate)

Actor/idol agency of similar scale (~97 employees vs. Billions ~86)

THE VC peer set

Mystic Story

Private

Music and actor management (~77 employees)

THE VC

P Nation

Private

Music-focused agency

THE VC

Big Ocean ENM

Private

Management

THE VC

Sublime

Private

Actor/creator management

THE VC

Blitzway Entertainment

KOSDAQ

Figures plus actor management; similar pivot from another core business

Asia Economy

KeyEast

KOSDAQ

Actor management, larger scale

Analyst identification

IHQ

KOSDAQ

Actor management and broadcasting

Analyst identification

Management SOOP / BH Entertainment / Kakao Ent. actor labels

Private / subsidiaries

Top-tier actor agencies with larger rosters and capital

Analyst identification

Peer Comparison FY2025

MetricBillions (FY2025)Fantagio

Revenue (KRW 100M)

253 (consolidated)

—

Revenue growth (%)

-39.3—

Operating margin (%)

-3.2—

Employees

~86 (Aug 2026)

97 (Aug 2026)

Company Snapshot

83

Employees

1973

Founded

Jeungpyeong-gun, South Korea

Headquarters

SWOT Analysis

Strengths

  • Recognisable artist roster. It includes Lee Jun-young (Four Hands, peak 9.4% rating, Oct 2026), Kim Ha-neul, Son Hyun-joo, Heo Sung-tae, Jo Bo-ah and K-pop vocalists Kim Sung-kyu, Nam Woo-hyun and Jung Eun-ji (Wikipedia; THE VC news).
  • Vertical integration. The absorption of XYG Studio (Nov 2025) plus the Billions Plus production arm allow planning, casting and production in one structure. Newtopia was delivered to Coupang Play (Money Today).
  • Repaired parent balance sheet. Separate equity rose from KRW 132.8 (100M) (FY2023) to 455.8 (1H 2026). Cash and short-term financial assets reached ~KRW 300.6 (100M) at 30 Jun 2026 (ValueLine).
  • Near break-even operations. Separate TTM operating income was positive in both Mar-2026 (4.6) and Jun-2026 (0.4) windows, after consolidated operating losses of −56 in FY2021 (ValueLine; Bullstory).
  • Committed controlling shareholder. Humasis and related parties hold 57.12%. Humasis funded both the 2025 rights offering and the KRW 10bn 2026 placement (TokenPost; The Bell).
  • 53-year manufacturing heritage. The company was the first KS-certified domestic condom and surgical-glove maker (1988), giving it a stable, if small, product line (Wikipedia).

Weaknesses

  • Chronic net losses. Consolidated net losses were −318, −247 and −308 (100M) in FY2021–FY2023, and −73 in FY2025. The separate TTM net loss reached −189 at Jun-2026 (Bullstory; ValueLine).
  • Accumulated deficit of ~KRW 97.4bn (consolidated, end-FY2025) against annual revenue of ~KRW 25bn (The Bell).
  • Interest burden. Separate interest expense of ~KRW 25 (100M) a year versus derived EBITDA of ~KRW 10–13 (100M) gives coverage below 0.5x (ValueLine; derived).
  • Thin gross margin of 18–22% on a separate basis, leaving little room after SG&A (ValueLine).
  • Strategic inconsistency. There have been six names since 2000 and four distinct strategic identities since 2017 (Edaily; THE VC).
  • Opaque disclosure. No segment, geographic or management-compensation data were publicly retrievable. Third-party databases carry stale officer lists (Investing.com; Statbase).

Opportunities

  • Overseas music monetisation. The Nam Woo-hyun Asia tour (Q4 2026) and a planned Japan label partnership (THE VC; Money Today).
  • OTT production pipeline through Billions Plus, leveraging in-house actors.
  • Aerospace supply-chain exposure. Tris grew revenue ~39% to ~KRW 29.8bn in 2025 with ~KRW 3.3bn operating profit and holds a long-term supply contract to 2039. That could support a re-rating if the theme holds (Asia Economy).
  • Group resources under Stella PE. Humasis reportedly holds more than KRW 200bn in cash, and Stella PE has signalled value-up plans across affiliates (The Bell).
  • Comeback-actor economics. Yoo Ah-in is cast in director Jang Jae-hyun's new film Vampir. If public sentiment recovers, the economics could be significant (IS Plus).
  • Lower float after consolidations, which reduces coin-stock delisting risk in the near term (TokenPost; The Bell).

Threats

  • Delisting and price risk. The KRX sub-KRW 1,000 rule forced two 25:1-equivalent consolidations within five months, after the stock fell from ~KRW 1,352 (post-first-consolidation, May 2026) to ~KRW 800 by August (Butler; Investing.com).
  • CB derivative volatility. The 1H 2026 derivative loss was KRW 149.9 (100M). Outstanding short-term bonds were KRW 100.9 (100M) at Jun-2026 (ValueLine).
  • Reputational risk. Yoo Ah-in remains under a suspended sentence until July 2027, and the signing drew a negative public reaction (IS Plus; Wikitree; Korea Daily).
  • Governance scrutiny. Humasis minority shareholders petitioned regulators over the KRW 48bn acquisition price and alleged "no-capital M&A" practices in the group (Newdaily, Oct 2024; Sidae, Jun 2025).
  • Associate losses. Equity-method losses of KRW 16–26 (100M) a year from associates, chiefly Kyungnam Pharm (ValueLine).
  • Market risk. KOSDAQ triggered a sell-side sidecar on 15 Oct 2026. Small-cap thematic names are most exposed (Money Today).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Apr 2025Actor Kim Ha-neul signed Global Epic via WikipediaHigh-profile roster addition
Jun 2025Dealsite reports group-wide sale talks; company denies a Billions sale Dealsite (19–20 Jun 2025)Ownership uncertainty
18–27 Jun 2025EGM approved 80% par reduction (KRW 500 → 100) DealsiteDeficit elimination
Jun 2025~KRW 11.6bn rights offering announced; Humasis to subscribe; Humasis minority shareholders object DealsiteRecapitalisation; governance friction
15 Jul 2025Capital-reduction record date DealsiteShare capital ~KRW 20.3bn → 4.1bn
1 Aug 20256th CB conversion price cut KRW 500 → 313; Kyungnam Pharm's potential stake rose to 34.66% Digital TodayDilution
8–19 Aug 2025Humasis acquired 13.57M subscription rights at KRW 187; special-securities stake reached 56.54% Digital TodayParent support
20 Aug 2025Kyungnam Pharm CB price reset to KRW 461 Digital TodayDilution mechanics
Aug 2025Actor Yu Ha-jin signed iMBC via WikipediaRoster
1 Sep 2025CB price reset upward (KRW 313 → 420) after a share-price rise Digital TodayDilution reduced
19 Sep 2025Rights-offering shares issued; Humasis held 36.43M shares (40.6%) Digital TodayControl consolidated
2 Oct 2025Shares outstanding reached 80,663,728; Kyungnam Pharm's CB-based stake fell to 18.2% Digital TodayPost-offering structure
14 Nov 2025Q3 2025 quarterly report filed KIND via WikipediaRoutine
Nov 2025Absorption of XYG Studio; Japan label deal flagged Money Today; Chosun BizIntegration
Mar 2026Stella PE agreed to acquire the Mirae I&G group package (KRW 120bn) The BellNew ultimate owner
20 Mar 2026KRW 10.0bn third-party placement (39.2M shares) DealsiteRecapitalisation
23 Mar 2026FY2025 annual results disclosed (consolidated revenue KRW 25.3bn; net loss KRW 7.3–7.4bn) Investing.com; Bullstory; The BellContinued losses
31 Mar 2026AGM: board reshuffle THE VC registryGovernance reset
9 Apr 2026Placement allottee changed to Humasis The BellParent funding
Apr–May 2026First 5:1 share consolidation (80.66M → 16.13M) The BellEscape coin-stock status
11 May 2026Digital Bridge New Technology Investment Association bought 5,377,945 shares at KRW 1,352 (~KRW 7.27bn), added as Humasis related party Butler (DART feed)Control bloc at 57.12%
27 May 2026Acquired a 3.97% stake in Tris for ~KRW 3.1bn Asia Economy; Money TodayAerospace / advanced-manufacturing theme
Aug 2026Second 5:1 consolidation (33.25M → 6.65M); trading halted 14 Aug–7 Sep StockHub (Edaily); TokenPostPrice had fallen back below KRW 1,000
11 Aug 2026Jung Eun-ji mini-album *Summer, I* released THE VC newsMusic revenue
21 Aug 2026Yoo Ah-in signed (suspended sentence runs to Jul 2027) IS Plus; The FactStar power vs. reputational risk
4 Sep 2026Humasis reported its stake maintained at 57.12% post-consolidation TokenPostControl stable
Sep 2026Go Won-hee signed TV ReportRoster
8 Sep 2026Consolidated shares relisted StockHubTrading resumed
14 Sep 2026Kim Ki-heung registered as CEO THE VC registryLeadership change
28 Sep 2026Lee Jung-jin signed TenAsia via WikipediaRoster
1–2 Oct 2026Jung Suk-yong cast in SBS *Doctor X*; Jo Bo-ah reviewing a lead offer Star News; OSEN via THE VCArtist bookings
Early Oct 2026Lee Jun-young's drama *Four Hands* ended with a peak 9.4% rating TenAsia via THE VCArtist value
14 Oct 2026Nam Woo-hyun's 2nd LP *2X8* released; Asia tour announced TenAsia; MHN Sports via THE VCMusic and concert revenue
15 Oct 2026Shares closed at KRW 2,900 (−4.45%) amid a market-wide KOSDAQ sell-off ValueLine; Money TodayMarket cap ~KRW 20.2bn

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

2 charts
Income Statement (KRW): Revenue separate to Operating income separate: Revenue separate fell from KRW 291.8 in Jun-2025 to KRW 245.8 in Jun-2026.
Blueberry NFT CO., LTD. — Income Statement (KRW): Revenue separate to Operating income separate
Series (KRW)Jun-2025Sep-2025Dec-2025Mar-2026Jun-2026
Revenue separate291.8277.8225.6256.5245.8
Cost of sales separate238.5228.6179.5204.4192
Gross profit separate53.249.1465253.8
SG&A separate56.448.648.847.453.3
Operating income separate-3.10.4-2.84.60.4

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Wikipedia — Billions (agency) (en.wikipedia.org)
  2. THE VC — Billions company profile (thevc.kr)
  3. THE VC — Billions Plus (thevc.kr)
  4. Bolta — Billions business registry data (bolta.io)
  5. JobKorea — Billions company page (m.jobkorea.co.kr)
  6. Statbase — Billions (044480.KQ) (statbase.ru)
  7. Investing.com — Billions Co Ltd (044480) profile (m.uk.investing.com)
  8. Investing.com — Billions Co Ltd (044480) quote (uk.investing.com)
  9. Bullstory — Billions annual financials (OpenDART data) (bullstory.io)
  10. DataHero / ValueLine — Income statement (valueline.co.kr)
  11. DataHero / ValueLine — Balance sheet (valueline.co.kr)
  12. Butler — Billions disclosures feed (butler.works)
  13. Pharm Edaily — Unidus transformation to NFT (16 Nov 2021) (pharm.edaily.co.kr)
  14. Dealsite — Blueberry NFT CB refixing (15 Sep 2022) (dealsite.co.kr)
  15. Dealsite — ELVN launch (15 Sep 2022) (dealsite.co.kr)
  16. Dealsite — Blueberry NFT / Danal MOU (Feb 2022) (dealsite.co.kr)
  17. Dealsite — Pixelground partnerships (Jan 2022) (dealsite.co.kr)
  18. Blockmedia — KPBPA NFT contract (Apr 2021) (blockmedia.co.kr)
  19. Asia Economy — STAN by B art NFT (Oct 2021) (core.asiae.co.kr)
  20. The Value News — Korbit / Blueberry Meta volleyball NFT (Nov 2022) (thevaluenews.co.kr)
  21. TokenPost — Korbit / Blueberry Meta (Nov 2022) (tokenpost.kr)
  22. Korea JoongAng Daily — MLD Entertainment MOU (koreajoongangdaily.com)
  23. SportBusiness — K League NFT deal (sportbusiness.com)
  24. Asia Economy — Star Village acquisition (Jan 2023) (core.asiae.co.kr)
  25. OSEN — Star Village acquisition (Jan 2023) (osen.co.kr)
  26. Dealsite — Humasis acquisition / Kyungnam Pharm (Jul 2024) (dealsite.co.kr)
  27. Newdaily — Humasis minority shareholders' legal action (Oct 2024) (biz.newdaily.co.kr)
  28. Newdaily — Humasis minority shareholders (Jul 2024) (biz.newdaily.co.kr)
  29. Daum — Group governance chain (Jul 2024) (v.daum.net)
  30. Daum — Kyungnam Pharm rights offering (Oct 2024) (v.daum.net)
  31. Daum — Minish Tech / Kyungnam Pharm (Jan 2025) (v.daum.net)
  32. Dealsite — Humasis funds Billions again (2025) (dealsite.co.kr)
  33. Dealsite — Billions capital reduction and rights offering (Jun 2025) (dealsite.co.kr)
  34. Dealsite — Kyungnam Pharm governance (2025) (dealsite.co.kr)
  35. Dealsite — Group sale rumours (Jun 2025) (dealsite.co.kr)
  36. Sidae / Money S — Group "no-capital M&A" scrutiny (Jun 2025) (sidae.com)
  37. Digital Today — Humasis stake reports (Aug–Sep 2025) (digitaltoday.co.kr)
  38. Digital Today — Humasis stake (Sep 2025) (digitaltoday.co.kr)
  39. Digital Today — Humasis stake (Sep 19, 2025) (digitaltoday.co.kr)
  40. Digital Today — Kyungnam Pharm CB holdings (Oct 2025) (digitaltoday.co.kr)
  41. Digital Today — Shim Hwa-seok rights acquisition (Aug 2025) (digitaltoday.co.kr)
  42. Money Today — XYG Studio merger (28 Nov 2025) (mt.co.kr)
  43. Money Today / The Bell — Stella PE and Humasis fund Billions (29 Apr 2026) (mt.co.kr)
  44. Dealsite — KRW 10bn placement (20 Mar 2026) (dealsite.co.kr)
  45. Dailypharm — Coin-stock consolidations (Mar 2026) (m.dailypharm.com)
  46. Asia Economy — Tris stake (27 May 2026) (core.asiae.co.kr)
  47. Money Today — Tris / SpaceX supply chain (27 May 2026) (mt.co.kr)
  48. StockHub (Edaily) — 5:1 consolidation (Aug 2026) (stockhub.kr)
  49. TokenPost — Humasis stake maintained at 57.12% (Sep 2026) (tokenpost.kr)
  50. IS Plus — Yoo Ah-in signs with Billions (21 Aug 2026) (isplus.com)
  51. The Fact — Yoo Ah-in signing (21 Aug 2026) (news.tf.co.kr)
  52. TV Report — Go Won-hee signing (Sep 2026) (tvreport.co.kr)
  53. PwC Governance Center — FSS 2026 focus areas (pwc.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.